PD-1 Antibody Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting pd-1 antibody clinical trials across 1 country. Studies span Phase 2, Phase 1. Top locations include Chengdu, Sichuan, China, Chongqing, Chongqing Municipality, China, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


PD-1 Antibody Trials at a Glance

6 actively recruiting trials for pd-1 antibody are listed on ClinicalTrialsFinder across 4 cities. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Chengdu, Chongqing, and Guangzhou. Lead sponsors running pd-1 antibody studies include The Second Affiliated Hospital of Chongqing Medical University, Nanfang Hospital, Southern Medical University, and Shanghai Jiao Tong University Affiliated Sixth People's Hospital.

Browse pd-1 antibody trials by phase

Treatments under study

About PD-1 Antibody Clinical Trials

Looking for clinical trials for PD-1 Antibody? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PD-1 Antibody trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PD-1 Antibody clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

EGFR Activating MutationLung Cancer Non-Small Cell Cancer (NSCLC)PD-1 Antibody
Nanfang Hospital, Southern Medical University32 enrolled1 locationNCT07637448
Recruiting
Phase 2

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Anti-PD-1 AntibodyChronic Hepatitis BPeg-IFNα
The Second Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT05771402
Recruiting
Phase 2

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Anti-PD-1 AntibodyChronic Hepatitis B
The Second Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT05769816
Recruiting
Phase 1Phase 2

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Rectal CancerRadiotherapyAnti-PD-1 Antibody+2 more
West China Hospital20 enrolled1 locationNCT04636008
Recruiting
Phase 2

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer

Cervical CancerRadiotherapyNeoadjuvant Chemotherapy+1 more
Shanghai Jiao Tong University Affiliated Sixth People's Hospital36 enrolled1 locationNCT05554276
Recruiting
Phase 2

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic CholangiocarcinomaApatinibTransarterial Chemoembolization+1 more
Sichuan Cancer Hospital and Research Institute20 enrolled1 locationNCT04834674